Table 2 Comparison of gene therapy strategies for GBM
Suicide gene therapy | Oncolytic gene therapy | Cytokine mediated gene therapy | Tumor suppressor gene therapy |
|---|---|---|---|
● Synergistic therapeutic efficiency of conventional treatment | ● Additional therapeutic transgenes available | ● Local augmentation of the immune response inside the brain | ● Anti-angiogenesis effect |
● Bystander effect | ● Selective toxicity | ● Combination therapy with other types of gene therapy available | ● Synergistic therapeutic efficiency of conventional or other of gene therapy |
● Selective cytotoxicity | ● Higher transduction efficiency | ● Reduce tumor vascularization and invasion | |
▲ Transduced cells may become resistant to the prodrug | ▲ Suppression of virus by host immune response | ▲ Lack of antigen presenting cells inside the brain | ▲ Resistance from the inherent genetic heterogeneity |
▲ Low efficiency for distribution | ▲ Cerebral inflammation and edema | ▲ CNS toxicity | ▲ Lack of bystander effect |
▲ Low delivery to target cells | ▲ Poor delivery of a gene to the tumor | ▲ Poor gene transfer | |
▲ Limited prolonged efficacy |